BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/12/2014 8:40:00 PM | Browse: 954 | Download: 788
Publication Name World Journal of Gastroenterology
Manuscript ID 4071
Country/Territory China
Received
2013-06-13 19:03
Peer-Review Started
2013-06-14 16:55
To Make the First Decision
2013-07-19 08:29
Return for Revision
2013-07-20 20:35
Revised
Second Decision
2013-08-20 10:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-08-20 12:41
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-09-17 19:29
Publish the Manuscript Online
2013-10-18 17:02
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Autobiography
Article Title De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis
Manuscript Source Invited Manuscript
All Author List Jiang-Shan Lian, Lin-Yan Zeng, Jian-Yang Chen, Hong-Yu Jia, Yi-Min Zhang, Dai-Rong Xiang, Liang Yu, Jian-Hua Hu, Ying-Feng Lu, Ling Zheng, Lan-Juan Li and Yi-Da Yang
Funding Agency and Grant Number
Funding Agency Grant Number
National Key Program for Infectious Diseases of China 2013ZX10002001 (to Yang YD)
12th Five-Year Significant New Drugs Creation Plan of the Ministry of Science and Technology of China 2011ZX09302-003-03 (to Yang YD)
Corresponding Author Dr. Yi-Da Yang, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. yangyida65@163.com
Key Words Chronic hepatitis B; Decompensated liver cirrhosis; Lamivudine; Adefovir dipivoxil; Combination therapy; Entecavir
Core Tip This study compared the de novo efficacy of combined lamivudine (LAM) and adefovir dipivoxil (ADV) therapy with that of entecavir (ETV) monotherapy for patients with hepatitis B virus (HBV)-related decompensated liver cirrhosis. Both LAM + ADV combination therapy and ETV monotherapy can effectively inhibit HBV replication, improve liver function, and decrease mortality. The data obtained in this study demonstrate the efficacy and the safety of these treatment regimens for 96 wk in patients with HBV-related decompensated liver cirrhosis.
Publish Date 2013-10-18 17:02
Citation Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(37): 6278-6283
URL http://www.wjgnet.com/1007-9327/full/v19/i37/6278.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i37.6278
Full Article (PDF) WJG-19-6278.pdf
Manuscript File 4071-Review.doc
Answering Reviewers 4071-Answering reviewers.pdf
Copyright License Agreement 4071-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 4071-Language certificate.pdf
Peer-review Report 4071-Peer reviews.pdf
Scientific Editor Work List 4071-Scientific editor work list.doc